NCT04434937

Open-Label Study of Parsaclisib, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213)

A Phase 2, Multicenter, Open-Label Study of Parsaclisib, a PI3Kδ Inhibitor, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213)

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 42 (actual)
• Sponsor: Incyte Biosciences Japan GK · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to assess the efficacy and safety of parsaclisib in Japanese participants with relapsed or refractory follicular lymphoma

Conditions

• Lymphoma

Interventions

Type	Name	Description
DRUG	parsaclisib	parsaclisib will be taken orally QD with water without regard to food except on mornings of PK clinic visits

Timeline

• Start date: 2020-09-30
• Primary completion: 2023-02-16
• Completion: 2023-10-13
• First posted: 2020-06-17
• Last updated: 2024-10-23
• Results posted: 2024-01-03

Locations

30 sites across 1 country: Japan

Regulatory

• FDA-regulated drug study